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Background: New prognostic markers may be of value in determining survival and informing decisions of adjuvant
treatment in the heterogeneous group of soft tissue sarcomas known as malignant fibrous sarcomas (MFS).
Increased CD44 expression has been associated with a better outcome in cancers such as bladder tumors and
could potentially relate to cell-cell interaction as a marker for potential invasion/metastasis. The aim of this pilot
study was to determine if there is a correlation between the expression rate of CD44 in adult patients with MFS
and clinical outcomes.
Methods: The clinical outcome of 34 adult MFS patients (19 males and 15 females, average age 62 years, median
63 years, range: 38–88 years) who underwent surgical treatment were evaluated. Twenty-five of these patients had
additional adjuvant radiotherapy. Extracted RNA from sarcoma tissues was used to measure the transcripts of CD44s
(standard form) and isoform expression.
The pooled data for each variant of CD44 was divided in half at the median expression value into two equally sized
groups (low and high). Survival modeling and multivariate analysis were used with these two groups to determine
if there were differences in survival times and whether this was independent of known factors such as tumor
stage/grade, patient age and resection margin status.
Results: High CD44s and low of CD44v6 expression significantly correlated with an improved outcome (P <0.05
and P <0.02, respectively) whereas CD44v8 and hCD44 (isoforms) did not. Differences in survival were apparent
within 6–12 months of operation with >30% difference in survival between low/high expressions at 5 years. These
finding were independent of the other measured MFS survival predictors, though the group was homogenous.
Conclusions: High CD44s and low CD44v6 expression may be an independent predictor of improved survival in
MFS patients in this pilot data. This is contrary to other MFS data, which did not account for the CD44 isoforms but is
confirmed by data from other cancer types. Further investigation is needed to confirm CD44 isoform expression data
as a relevant survival biomarker and whether it could be used to inform clinical decisions such as adjuvant therapy.
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Soft tissue sarcomas (STS) are a clinically and pathologic-
ally heterogeneous group of tumors that lead to therapeutic
difficulties. The most frequent histological type is malignant
fibrous histiocytoma, which is a heterogeneous group in it-
self, accounting for approximately 30% of STS. The origin
of these tumors may come from undifferentiated mesen-
chymal stem cells from fibroblasts or dual fibroblastic-
histiocytic origin [1-11]. Although not presently accepted
by all, it has been suggested that the term myxofibrosar-
coma or malignant fibrous sarcoma (MFS) should be used
for the myxoid variant of malignant fibrous histiocytoma
[1] and this nomenclature will be used for the rest of this
communication.
Prognostic favorable outcome of MFS depends on early
diagnosis and aggressive but limb-sparing treatment [1].
The most important prognostic factor identified so far
is the quality of surgical treatment at initial diagnosis
[2]. Meanwhile, new prognostic factors are sought in
order to specifically assess the importance of an adju-
vant or palliative therapy.
Cell-to-cell and cell-to-matrix interactions are essen-
tial for normal cell growth and differentiation, though
their precise function remains unclear. A variety of ad-
hesion molecules participate in these interactions includ-
ing the hyaluronic acid binding cell surface glycoprotein
CD44. CD44 is expressed on all cell types and acts as a
receptor for hyaluronate [12,13]. Therefore, CD44 may
play a role in cellular differentiation/migration and cell-to-
cell-contact. In aberrant gene expression within sarcomas,
CD44 could play a role especially for invasion, such that
may lead to lymph node or distant metastases and thus
plays a role in prognosis.
CD44’s encoding gene is located on chromosome 11p3
and consists of at least 21 exons [14]. The CD44 molecule
consists of three core epitopes encoded by ten exons with
alternative mRNA splicing of the remaining exons generat-
ing multiple isoforms. The standard form of CD44 (CD44s)
is expressed on almost all cells and is heavily glycosylated,
while variant isoforms are expressed in a cell- and tissue-
specific manner [15]. Post-translational modifications, such
as glycosylation and alternative splicing, add even further to
the diversity of the function of the special CD44 isoforms.
The standard form of CD44 as well as its variants is
widely expressed in several tissue types but there are
conflicting reports about the associations between CD44v
and patients’ prognosis. High levels of CD44 and CD44v
have been associated with poor outcomes in breast cancer,
gastric cancer, colorectal carcinoma and head/neck cancer
[3-6]. However, several studies have shown that CD44 ex-
pression is associated with a better outcome in cancers
such as bladder tumors and other studies have suggested
no direct association of CD44 with prognosis in cancers
such as skin tumors [7,8].Few studies have investigated CD44 expression by STS,
especially in MFS. In an earlier immunohistochemical
investigation, we determined that CD44s-positive STS
cells significantly correlated with longer survival [9]. The
aim of this study was to evaluate the isoforms of CD44 ex-
pression in adult STS and to determine whether this could
provide prognostic information.
Methods
This is a retrospective multicenter pilot study performed
on MFS tissue obtained from the tumor banks of the
Department of Surgery, Heinrich-Heine-University,
Düsseldorf, and the Department of Plastic Surgery,
Ruhr University, Bochum. Patient data were collected
retrospectively starting at the time of specimen collection
until the end of the study observation period. The study
was approved by the local ethical commission board from
the University of Dusseldorf. (Study No. 4487). All tumor
specimens were reviewed by one experienced pathologist
as well as a national sarcoma reference center to confirm
the diagnosis of MFS.
Pretreatment evaluation included a complete history
and physical examination, chest CT or chest radiograph,
and computed tomographic or magnetic resonance im-
aging scans of the tumor site as well as routine ECG
and pulmonary function tests, if needed. In all cases,
treatment options were discussed in an interdisciplin-
ary tumor conference. All patients were subsequently
resected with a curative intention. In three patients, re-
section was performed despite distant metastases ei-
ther because of the young age or the explicit wishes of
the patient. Based on the tumor size and anatomic site,
either a complete/compartment resection or wide local
excision was performed. Tumor staging was performed
according the UICC TNM-System (1997).
Frozen tumor samples were cut in 20-μm thick sections
with a cryostat. Ten sections were immediately placed in
an Eppendorf tube and total RNA was extracted by using
the TRIzol reagent (Invitrogen, USA) according to the
manufacturer’s instructions. RNA concentration was veri-
fied spectrophotometrically (BioPhotometer, Eppendorf,
Germany) by using the OD260 method. Reverse transcrip-
tion was performed in a volume of 20 μL by using random
hexamer primer, 2 μg RNA and reverse transcriptase in
5× RT-buffer (all from Roche Diagnostics, Germany).
Quantitative PCR with cDNA was performed using the
iQ Sybr Green Supermix (BioRad). PCR conditions and
primer sequences for CD44, CD44 isoforms, and the
reference genes beta-actin and beta-microglobulin, were
selected as previously described [10] with the exception
that the annealing temperature for CD44v8 was changed
to 58°C and that of CD44s to 54°C. For relative quantifica-
tion and to normalize the amount of the CD44 product
and the CD44 isoform products, we applied the delta-CT
Table 1 Characteristics of the patients
Patients (n) Patients (%)
pT1-category 4 12
pT2-category 30 88
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actin or beta-microglobulin, respectively. The expression
rate of CD44 was correlated to the TNM category, resec-
tion status, grading, tumor size, and tumor free and over-




R1 3 11Statistical analysis
Data analysis was performed through grouping of the mea-
sured expression by separating patients into two equally
sized groups at the median (high and low expression) for
each isoform. Survival curves were determined using the
Kaplan-Meier estimator and compared by the log-rank
test with 95% confidence intervals based on Greenwood’s
formula [16]. Prognostic risk factors of patient survival
(TNM-category, tumor size, resection margin status, hist-
ology, grade, and patient age) were evaluated by univariate
and multivariate analysis. The Cox proportional-hazards
regression model was used to determine risk factors
and hazard ratios [17]. Two-tailed values of P <0.05
were considered significant.Results
In total, we examined 34 adult MFS patients (19 males
and 15 females, average age 62 years, median 63 years,
ranged from 38 to 88 years). MFS was confirmed in all
tumor specimens after surgical treatment. Eleven patients
underwent operation for recurrent disease, while 23 pa-
tients were operated on the primary tumor. The majority
of patients received adjuvant radiotherapy (n = 25), while
no patient received adjuvant chemotherapy. All MFS tu-
mors were graded G3. Complete histological evaluation of
the tumor specimen revealed four T1 tumors (12%), while
30 patients had a tumor of >5 cm in diameter (T2, 88%).
In all patients, regional lymph nodes were either clinically
or histologically without metastases (100%). Three patients
presented with synchronous distant metastases (11%), while
staging procedures revealed M0 in 31 patients (89%). In all
four patients with a subcutaneous tumor (12%), a wide re-
section resulted in four R0 resections. In the 30 patients
with a subfascial MFS, four patients (12%) had a compart-
mental resection performed, resulting in R0. Twenty-six
tumors were resected with a wide excision, achieving
tumor-free margins in 23 patients (68%). In three patients
(8%), an R1 resection with narrow margins was performed
to preserve large nerves surrounded by the tumor, to drain
a seroma by primary incisional biopsy during resection, or
due to a patient denying primary amputation (Table 1).
The mean survival was 54 ± 6 months. The tumor re-
curred locally in one patient after resection (3%). Dis-
tant metastases developed in nine patients (26%) after
a median of 19 months (range 4–48 months). At the
end of the follow-up period, 24 patients (71%) were
without evidence of disease; all patients that developeddistant metastases (n = 19, 29%) died from their tumor
within a median of 24 months.
The grouping into two groups by the analyzed variants of
CD44 (hCD44, hCD44s, hCD44v6, and hCD44v8) showed
a significant difference in tumor related survival only for
CD44s and CD44v6 (P <0.05 and P <0.02, respectively).
Visualization of the Kaplan-Meier estimates for the four
isoforms of CD44 is shown in Figures 1, 2, 3, and 4. In pa-
tients with an increased expression of the hCD44s isoform,
there was a significantly longer overall survival with a
5-year survival rate of >80% compared to 50% in patients
with a loss of hCD44s. Furthermore, we noticed a survival
benefit in patients with a loss of CD44v6 isoform, again
with a 5-year survival of >80% compared to 50% in patients
with a CD44v6 positive sarcoma. The survival curves begin
to diverge as early as 6 months after resection.
CD44s and CD44v6 were independent predictive markers
for the outcome of our patients when it was controlled for
stage, tumor grade, age and margin status.
However, a significant correlation to the TNM-category,
especially to metastases, the histology of the specimen,
resection status and tumor size could not be found. This
may be due to the low number of M1 and R1 cases with
all specimens graded G3. Correlation between CD44 ex-
pression and tumor depth did not quite reach a signifi-
cant value (P >0.5).
Discussion
Qualitative and quantitative changes in expression of CD44
and its isoforms have been demonstrated for several tumor
models revealing prognostic significance for neuroblastoma
[18], breast cancer [13], squamous cell esophageal cancer
[19], osteosarcoma [20], and gastric cancer [21]. Only few
reports exist about survival and CD44s expression in STS
[9] and rhabdomyosarcoma [15]. We could not find any
report focusing on MFS sarcomas. A recent study exam-
ined CD44v expression in a variety of STS and noted that
expression of CD44v6 is more frequently detected in
high-grade than in low-grade tumors [22]. They described
a correlation with metastases-free survival in these patients
although overall patient number was small. Maula et al. ob-
served similar results in a recently published observation of
Figure 1 Kaplan-Meier estimates for hCD44.
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patients with several STS entities, we detected a prognostic
benefit if CD44s was highly expressed [9].
Here, we found significant differences between the CD44
high expression group and CD44 low expression group
regarding overall survival. Though the role of CD44 in
metastasis remains unclear, CD44 may be important
during invasion of the target organs, perhaps by interaction
of the molecules with special ligands (e.g., collagen, fibro-
nectin, osteopontin) [24]. Changes in adhesion molecules
that participate in cell-cell boundaries and cell-matrix inter-
actions are a prerequisite for tumor invasion and dissemin-
ation. In STS, expression of cell-surface antigen CD44 has
been associated with local recurrence [23] and, in particular,
the isoform CD44v6 has been correlated with metastatic
disease [22]. However, we could not confirm these results
with our data. The measured CD44 isoforms did not correl-
ate with metastases in our patients. Our results are in lineFigure 2 Kaplan-Meier estimates for hCD44s.with a study by Kahara et al. [22], where they found that in-
creased CD44v6 at the protein level was associated with a
poor clinical outcome. Nilbert et al. found no differences in
the expression of CD44 in MFS primary tumors, local re-
currences or metastases, nor could they find any correlation
between CD44 and prognosis [25]. However, it should be
noted that the CD44v isoform was not analyzed, which
could possibly explain the lack of prognostic importance.
In our study, the strong correlation between CD44
expression and actuarial survival revealed CD44 as a
strong prognostic marker. CD44 expression is not the
only independent prognosticator for STS; in fact, previous
studies have shown that the resection margin and tumor
size represent independent prognostic indicators [25].
Tumor depth almost reached significance in our study
but other well-described factors, such as tumor grade,
did not. This may be due to the relative homogeneity
of our patient cohort with all G3 tumors and few M1 at
Figure 3 Kaplan-Meier estimates for hCD44v6.
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eity of the cohort is also strength to the study as it may help
to inform decisions about this relatively common cohort
among MFS patients. Future studies with larger and more
diverse cohorts are needed to define the precise role of this
cell adhesion molecule in invasion and metastases of MFS.
Nevertheless, the association between CD44s expression
and progression of MFS is important, as it suggests that
CD44s may play a protective role in tumor progression.
The overexpression of CD44v6 in some tumor types
has been correlated to metastatic potential. The different
CD44v proteins originate in alternative splicing of variant
exons at the copying stage and are expressed in several
cancer types. CD44v6 overexpression was found in
metastatic breast cancer [26]. Recently, overexpression
of CD44v6 was described in squamous cell cancer with a
significant correlation between abnormally high expressionFigure 4 Kaplan-Meier estimates for hCD44v8.of CD44v6 and infiltration in surrounding tissue as well
as metastatic disease [27]. CD44v6 was only expressed
in metastatic cell strains, but not in non-metastatic cell
lines [11]. The non-metastatic cell lines gained metastatic
potential after transfection with CD44v6.
While CD44s is a candidate tumor suppressor in MFS,
CD44v6 may function as an oncogene. This is consistent
with prostate cancer, in which CD44s is a tumor suppres-
sor but certain CD44 variants are oncogenes and promote
growth [28,29]. Since MFS is a heterogeneous group of tu-
mors nowadays often classified as sarcoma not otherwise
specified (NOS), several tumor entities may be summa-
rized under this term. Further classification of MFS-NOS
does not exist at present but clinical experience has shown
that there are patients with MFS-NOS with an extremely
poor prognosis, while others can be cured through sur-
gery alone. A positive impact of chemotherapy on patient
Matuschek et al. European Journal of Medical Research 2014, 19:6 Page 6 of 7
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pression [20]. Therefore, a prospective cohort study
design should be performed to analyze if a treatment
escalation can improve the clinical outcome of these
patients. Further evaluation of CD44v6 expression as an
important prognostic and predictive biomarker is needed
before clinical use.
Conclusions
Our study suggests that low expression of CD44s as
well as high expression of CD44v6 correlates with poor
outcome. Although the cohort was relatively homogenous,
these correlations were independent of other survival pre-
dictors; thus, further studies are needed to determine if they
may be clinically useful.
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